

# Bit Market Services

Informazione Regolamentata n. 0696-170-2015	Data/Ora Ricezione 12 Dicembre 2015 00:18:59	MTA
---	--	-----

Societa' : CTI BIOPHARMA  
Identificativo : 66850  
Informazione  
Regolamentata  
Nome utilizzatore : CELLN02 - Bell  
Tipologia : IRAG 10  
Data/Ora Ricezione : 12 Dicembre 2015 00:18:59  
Data/Ora Inizio : 12 Dicembre 2015 00:34:00  
Diffusione presunta  
Oggetto : CTI BIOPHARMA FILES FORM 8-K

*Testo del comunicato*

Vedi allegato.



## CTI BIOPHARMA FILES FORM 8-K

**SEATTLE, Wash., December 11, 2015**—CTI BioPharma Corp. (“CTI BioPharma”) (MTA: CTIC) today announced it has filed a Form 8-K with the U.S. Securities and Exchange Commission (“SEC”). Information in the Form 8-K is as follows:

On December 11, 2015, CTI BioPharma Corp. (the “Company”) and its wholly-owned subsidiary, Systems Medicine LLC (together with the Company, the “Borrower”), entered into a Fourth Amendment (the “Amendment”) to the Loan and Security Agreement dated March 26, 2013, as amended (as amended prior to the Amendment, the “Original Loan Agreement”, and the Original Loan Agreement as amended by the “Amendment”, the “Facility”) with Hercules Technology Growth Capital, Inc., as administrative agent, and the lenders party thereto (collectively, the “Lender”). Pursuant to the Amendment, the Lender agreed to fund the remaining \$5.0 million term loan available under the Facility on the date of the Amendment. On December 11, 2015, \$5.0 million (less fees and expenses) was funded, thereby resulting in a current outstanding principal balance under the Facility of \$25.0 million (collectively, the “Term Loan Borrowings”). Under the Amendment, the applicable milestone event that the Borrower is required to satisfy to extend the interest-only period until June 30, 2016 (as further described below) is amended such that such milestone will be satisfied upon receipt by Lender on or before March 31, 2016 of satisfactory evidence that the Borrower has submitted to the United States Food and Drug Administration (“FDA”) the fully completed new drug application for pacritinib (the “Pacritinib NDA”), and the FDA has confirmed in writing acceptance of the Pacritinib NDA (“Milestone Event No. 2”).

The interest rate on the Term Loan Borrowings floats at a rate per annum equal to 10.95% plus the amount by which the prime rate exceeds 3.25%. The Borrower is initially required to make interest payments only on a monthly basis, and the principal amount of the Term Loan Borrowings is repayable over 36 monthly installments commencing on January 1, 2016. The interest-only period may be extended, at the Borrower’s option, by three months if the Lender receives on or prior to December 31, 2015 satisfactory evidence that the Borrower has achieved full patient enrollment for the PERSIST-2 Phase 3 clinical trial for pacritinib and by an additional three months if the Borrower satisfies the Milestone Event No. 2 prior to April 1, 2016. The Term Loan Borrowings will mature on December 1, 2018. The Borrower may elect to prepay some or all of the Term Loan Borrowings at any time subject to a prepayment fee, if any, pursuant to the terms of the Facility. Under certain circumstances, the Borrower may be required to prepay the Term Loan Borrowing with proceeds of asset dispositions. The Term Loan Borrowings are secured by a first priority security interest on substantially all of the Company’s personal property except its intellectual property and subject to certain other exceptions.

The Borrower paid a facility charge of \$50,000 in connection with the Amendment.

The Facility contains certain representations and warranties, covenants and conditions that are customarily required for similar financings and certain events of default (subject, in certain instances, to specified grace periods) including, but not limited to, the failure to make requisite payments of interest or premium, if any, on, or principal, the failure to comply with certain covenants and agreements, the occurrence of a material adverse

effect, defaults in respect of certain other indebtedness and certain events of insolvency. If any event of default occurs, all monetary obligations owing under the Facility may become due and payable immediately.

For more detailed information, please refer to the Current Report on Form 8-K that has been filed with the SEC and is available on the SEC website at [www.sec.gov](http://www.sec.gov), as well as CTI BioPharma's website at [www.ctibiopharma.com](http://www.ctibiopharma.com).

### **Forward Looking Statements**

This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI BioPharma's securities. Such statements include, but are not limited to, statements regarding the development of CTI BioPharma. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and are based on assumptions about many important factors and information currently available to us. Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI BioPharma and its product and product candidate portfolio in particular, as well as other risks listed or described from time to time in CTI BioPharma's most recent filings with the SEC on Forms 10-K, 10-Q and 8-K. Except as required by law, CTI BioPharma undertakes to update its forward-looking statements.

Source: CTI BioPharma Corp.

### **Contacts:**

Monique Greer  
+1 206-272-4343  
[mgreer@ctibiopharma.com](mailto:mgreer@ctibiopharma.com)

Ed Bell  
+1 206-272-4345  
[ebell@ctibiopharma.com](mailto:ebell@ctibiopharma.com)

Fine Comunicato n.0696-170

Numero di Pagine: 4